

Dicot Pharma presents at Aktiespararnas' event Aktiedagarna on June 9

Uppsala, Sweden, June 5, 2026. Dicot Pharma AB will be participating in Aktiespararnas' investor meeting Aktiedagarna, which is organized at Hotel Birger Jarl in Stockholm, on Tuesday, June 9, 2026. At 1:30 PM, CEO Elin Trampe will present the company, and the presentation can be viewed digitally via link, both live and afterwards. The presentation will be in Swedish.

Dicot Pharma's CEO Elin Trampe will present the company and its drug candidate LIB-01, which is being developed as a unique, long-acting treatment for erectile dysfunction. The company is currently preparing for a clinical phase 2b study with LIB-01 in Europe and the US.

The presentation starts at 1.30 PM and can be followed live via the following link: <https://invitepeople.com/public/events/fa647c6285/pages/ea19175b1c>. The presentation will be recorded and made available for viewing afterward, including on Dicot Pharma's website.

For further information, please contact:

Elin Trampe, CEO

Phone: +46 72 502 10 10

E-mail: elin.trampe@dicotpharma.com

About Dicot Pharma AB

Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market.

Dicot Pharma is listed on Nasdaq First North and has approximately 16,750 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.